CME Total Revenue vs Cost Of Revenue Analysis
CME Stock | USD 213.14 0.41 0.19% |
CME financial indicator trend analysis is way more than just evaluating CME Group prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether CME Group is a good investment. Please check the relationship between CME Total Revenue and its Cost Of Revenue accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CME Group. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.
Total Revenue vs Cost Of Revenue
Total Revenue vs Cost Of Revenue Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of CME Group Total Revenue account and Cost Of Revenue. At this time, the significance of the direction appears to have almost identical trend.
The correlation between CME's Total Revenue and Cost Of Revenue is 0.96. Overlapping area represents the amount of variation of Total Revenue that can explain the historical movement of Cost Of Revenue in the same time period over historical financial statements of CME Group, assuming nothing else is changed. The correlation between historical values of CME's Total Revenue and Cost Of Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Revenue of CME Group are associated (or correlated) with its Cost Of Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cost Of Revenue has no effect on the direction of Total Revenue i.e., CME's Total Revenue and Cost Of Revenue go up and down completely randomly.
Correlation Coefficient | 0.96 |
Relationship Direction | Positive |
Relationship Strength | Very Strong |
Total Revenue
Total revenue comprises all receipts CME Group generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Cost Of Revenue
Cost of Revenue is found on CME Group income statement and represents the costs associated with goods and services CME provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.Most indicators from CME's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into CME Group current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CME Group. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. At present, CME's Enterprise Value is projected to increase significantly based on the last few years of reporting.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 3.9B | 4.3B | 4.5B | 2.5B | Total Revenue | 4.7B | 5.0B | 5.6B | 3.0B |
CME fundamental ratios Correlations
Click cells to compare fundamentals
CME Account Relationship Matchups
High Positive Relationship
High Negative Relationship
CME fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 75.2B | 124.7B | 196.8B | 174.2B | 129.8B | 136.3B | |
Short Long Term Debt Total | 3.7B | 3.4B | 3.4B | 3.4B | 3.9B | 2.4B | |
Other Current Liab | 38.5B | 88.1B | 159.6B | 132.2B | 93.3B | 98.0B | |
Total Current Liabilities | 38.5B | 88.2B | 160.4B | 137.7B | 93.4B | 98.1B | |
Total Stockholder Equity | 26.1B | 26.3B | 27.4B | 26.9B | 26.7B | 17.6B | |
Other Liab | 6.2B | 6.7B | 6.3B | 5.7B | 6.6B | 6.2B | |
Property Plant And Equipment Net | 544M | 579.2M | 505.3M | 455.5M | 681.5M | 483.4M | |
Net Debt | 2.2B | 1.8B | 610.2M | 718.3M | 966.7M | 843.5M | |
Retained Earnings | 5.0B | 5.0B | 5.2B | 4.7B | 4.5B | 3.0B | |
Accounts Payable | 61.9M | 69.3M | 48.8M | 121.4M | 90.6M | 51.7M | |
Cash | 1.6B | 1.6B | 2.8B | 2.7B | 2.9B | 3.1B | |
Non Current Assets Total | 35.6B | 35.4B | 35.0B | 35.1B | 34.8B | 24.0B | |
Non Currrent Assets Other | 2.1B | 2.0B | 3.3B | (3.1B) | 514.1M | 1.0B | |
Other Assets | 545.9M | 7.3B | 3.3B | 574M | 134.4M | 127.7M | |
Long Term Debt | 3.7B | 3.4B | 2.7B | 3.4B | 3.4B | 2.5B | |
Cash And Short Term Investments | 1.6B | 1.7B | 2.9B | 2.8B | 3.0B | 2.7B | |
Net Receivables | 491.8M | 461.3M | 434.5M | 483.2M | 1.3B | 1.3B | |
Common Stock Shares Outstanding | 358.2M | 358.5M | 358.9M | 359.2M | 359.5M | 311.9M | |
Liabilities And Stockholders Equity | 75.2B | 124.7B | 196.8B | 174.2B | 129.8B | 136.3B | |
Non Current Liabilities Total | 10.5B | 10.1B | 9.0B | 9.6B | 9.6B | 7.4B | |
Other Current Assets | 360.1M | 302M | 423M | 524.9M | (4.3B) | (4.1B) | |
Other Stockholder Equity | 21.1B | 21.2B | 22.2B | 22.3B | 22.3B | 14.5B | |
Total Liab | 49.1B | 98.3B | 169.4B | 147.3B | 103.1B | 108.3B | |
Property Plant And Equipment Gross | 544M | 579.2M | 505.3M | 455.5M | 1.3B | 1.4B | |
Total Current Assets | 39.6B | 89.3B | 161.8B | 139.1B | 94.9B | 99.6B | |
Accumulated Other Comprehensive Income | 3.4M | 134.9M | 53.5M | (133.3M) | (55.6M) | (52.8M) | |
Property Plant Equipment | 544M | 579.2M | 505.3M | 837.6M | 963.2M | 490.1M | |
Short Term Investments | 83.2M | 100.9M | 115M | 96M | 111.7M | 106.1M | |
Inventory | 37.1B | 86.8B | 158.0B | 135.3B | 155.5B | 163.3B | |
Short Term Debt | 49.7M | 52.2M | 749.4M | 16M | 55.1M | 52.3M | |
Intangible Assets | 22.3B | 22.0B | 20.7B | 20.4B | 20.2B | 18.4B | |
Good Will | 10.7B | 10.8B | 10.5B | 10.5B | 10.5B | 8.9B | |
Retained Earnings Total Equity | 4.9B | 5.0B | 5.0B | 5.2B | 5.9B | 3.7B | |
Deferred Long Term Liab | 5.7B | 5.6B | 5.6B | 5.4B | 6.2B | 4.7B | |
Net Tangible Assets | (6.9B) | (6.5B) | (3.8B) | (4.0B) | (4.7B) | (4.9B) | |
Long Term Debt Total | 3.8B | 3.7B | 3.4B | 2.7B | 3.1B | 2.9B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether CME Group is a strong investment it is important to analyze CME's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact CME's future performance. For an informed investment choice regarding CME Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CME Group. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Complementary Tools for CME Stock analysis
When running CME's price analysis, check to measure CME's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CME is operating at the current time. Most of CME's value examination focuses on studying past and present price action to predict the probability of CME's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CME's price. Additionally, you may evaluate how the addition of CME to your portfolios can decrease your overall portfolio volatility.
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Transaction History View history of all your transactions and understand their impact on performance | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |
Is CME's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CME. If investors know CME will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CME listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.03) | Dividend Share 4.45 | Earnings Share 8.78 | Revenue Per Share 15.638 | Quarterly Revenue Growth 0.032 |
The market value of CME Group is measured differently than its book value, which is the value of CME that is recorded on the company's balance sheet. Investors also form their own opinion of CME's value that differs from its market value or its book value, called intrinsic value, which is CME's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CME's market value can be influenced by many factors that don't directly affect CME's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CME's value and its price as these two are different measures arrived at by different means. Investors typically determine if CME is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CME's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.